Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial

LANDRAY M., HAYNES R., STAPLIN N., SPATA E., PETO L., KNIGHT M., MAFHAM M., EMBERSON J., HORBY P.

Type

Journal article

Journal

Lancet Child and Adolescent Health

Publisher

Elsevier

Publication Date

20/11/2023

Permalink